Status:

WITHDRAWN

Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris

Lead Sponsor:

Wayne State University

Conditions:

Postinflammatory Hyperpigmentation

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

PHASE3

Brief Summary

The goal of this study is to determine if topical tranexamic acid is capable of decreasing the pigment of the dark spots left from acne bumps. The first line medication used for this often is not tole...

Eligibility Criteria

Inclusion

  • Age 18 to 65
  • Patients with bilateral involvement of facial postinflammatory hyperpigmentation due to acne vulgaris.

Exclusion

  • Pregnant patients or patients planning to become pregnant during the time of the study.
  • Patients with a history of use of hydroquinone, kojic acid, tretinoin, adapalene, tazarotene or azaleic acid in the previous 3 months.

Key Trial Info

Start Date :

November 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 9 2022

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT03361345

Start Date

November 1 2018

End Date

January 9 2022

Last Update

May 16 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

WSUPG Dermatology

Dearborn, Michigan, United States, 48124

Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris | DecenTrialz